Equities

Fine Foods & Pharmaceuticals NTM SpA

Fine Foods & Pharmaceuticals NTM SpA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)8.30
  • Today's Change-0.04 / -0.48%
  • Shares traded2.18k
  • 1 Year change0.00%
  • Beta0.5118
Data delayed at least 15 minutes, as of Mar 28 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fine Foods & Pharmaceuticals NTM SpA, formerly Innova Italy 1 SpA, is an Italy-based pharmaceutical company. It is specialized in the manufacturing of pharmaceutical products for third parties. The Company manages three segments: Pharmaceuticals, Nutraceuticals and Medical Devices. The Pharmaceuticals segment includes powders and granules, tablets, coated tablets and hard gelatin capsules, packaged in sachets, blisters and bottles. The Nutraceuticals segment includes soluble and effervescent powders and granules, soluble, effervescent and chewable tablets, coated tablets and hard gelatin capsules packaged in bags, sachets, sticks, jars, tablet bottles, blisters and strips. The Medical Devices segment includes tablets, capsules, powders, granules and cover the areas for gastrointestinal, oral and throat treatment and the weight management. Medical Devices marked CE (European Conformity) are available for licensing.

  • Revenue in EUR (TTM)239.72m
  • Net income in EUR627.77k
  • Incorporated--
  • Employees748.00
  • Location
    Fine Foods & Pharmaceuticals NTM SpAVia Berlino, 39, ZingoniaVERDELLINO 24040ItalyITA
  • Websitehttps://www.finefoods.it
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eurobio Scientific SA128.01m7.91m165.01m304.0021.321.046.771.290.75520.755211.9115.450.48563.754.48948,222.303.0021.703.5328.7945.2850.596.1825.062.704.110.37990.00-17.3829.03-58.81---6.24--
Genfit SA29.75m-34.17m166.45m154.00--2.23--5.59-0.6877-0.68770.59881.500.1381535.2516.86201,027.00-15.86-15.88-19.53-19.0292.8094.23-114.87-120.192.95-9.320.5030---68.9631.11-135.27------
Allergy Therapeutics plc62.32m-58.76m167.31m635.00--5.40--2.68-0.0266-0.02660.0170.00560.75712.214.9283,870.87-71.39-11.59-102.10-15.1552.5470.08-94.29-11.780.9281-7.930.2713---18.11-2.71-212.65--16.41--
Avantium NV19.70m-31.40m168.12m262.00--2.36--8.53-0.631-0.6310.38510.89470.10052.271.8475,190.84-17.42-23.26-23.76-30.6183.0783.15-173.35-186.671.00--0.6689--10.5111.79-11.64--61.87--
Egetis Therapeutics AB (publ)4.98m-28.32m169.32m25.00--3.58--33.99-1.28-1.280.2241.860.08716.923.59---49.44-33.02-55.92-36.4680.87---568.00-357.723.32--0.1688--154.8715.35-68.68------
Aelis Farma SA5.55m-5.57m171.69m22.00--9.98--30.92-0.4123-0.41230.41871.300.1405--1.36252,409.10-14.09-30.28-22.24-49.56-----100.29-168.222.41--0.1337---58.03---2,589.20------
Inventiva SA14.01m-80.08m173.02m117.00------12.35-1.90-1.900.3357-0.1820.1564--12.60124,008.90-89.37-40.86-136.45-49.44-----571.45-747.461.37-25.031.28--190.3920.48-9.35--5.56--
Innate Pharma SA51.90m-7.57m176.68m191.00--3.39--3.40-0.0843-0.08430.6170.64370.2648--1.77---3.86-8.83-4.87-12.1165.19---14.59-55.55----0.6408--4.68-8.2786.94--10.50--
Cellectis SA22.63m-54.96m178.52m----1.96--7.89-1.05-1.540.43911.270.0998--40.86---27.15-21.38-34.66-26.37---61.60-272.10-268.89---4.960.5559---33.35-5.27-5.77---14.21--
Celon Pharma SA50.25m-5.84m179.21m513.00--1.6825.393.57-0.4927-0.49274.249.010.35612.116.26413,906.30-4.14-0.3415-4.79-0.381767.6772.23-11.61-1.301.89--0.0349---2.2712.68-238.39--1.59-11.94
Fine Foods & Pharmaceuticals NTM SpA239.72m627.77k183.10m748.00--1.5810.930.7638-0.0131-0.013110.415.260.83543.915.93320,484.800.21880.7390.30230.99626.7828.360.26190.95481.24--0.4338--6.16---565.93--526.21--
Genovis AB13.71m5.33m189.44m37.0035.5511.4630.7013.820.93940.93942.422.910.7203----4,276,514.0027.9918.5630.7421.4572.2065.5138.8723.88--------54.5435.56449.56------
Laboratorio Reig Jofre SA316.09m9.41m198.29m1.32k34.540.96027.100.62730.07210.07214.012.590.972.405.98240,188.502.882.143.872.7958.2861.392.972.650.7839873.290.2075--16.5711.8616.040.3019-9.54--
Avacta Group Plc18.75m-49.24m204.04m120.00--6.02--10.88-0.1605-0.16330.06060.08260.24064.502.38133,541.70-63.18---119.23--54.40---262.60--0.6603-1.660.6913--228.22---49.92------
Probi AB54.38m1.46m208.29m168.00142.941.7621.273.831.481.4855.09120.160.41023.507.42--1.104.641.164.9835.0842.042.689.835.44--0.037821.421.520.7684-58.60-26.0931.01--
Data as of Mar 28 2024. Currency figures normalised to Fine Foods & Pharmaceuticals NTM SpA's reporting currency: Euro EUR

Institutional shareholders

11.21%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 2023607.01k2.75%
AcomeA SGR SpAas of 30 Jun 2023440.18k2.00%
Amundi SGR SpAas of 31 Jan 2024380.00k1.72%
Azimut Capital Management SGR SpAas of 29 Feb 2024228.15k1.03%
Lupus alpha Asset Management AGas of 30 Jun 2023220.00k1.00%
Kairos Partners SGR SpAas of 30 Jun 2023176.31k0.80%
Mediolanum Gestione Fondi SGRpAas of 29 Sep 2023170.95k0.78%
BG Fund Management Luxembourg SAas of 30 Jun 2023100.27k0.46%
Mandarine Gestion SAas of 30 Jun 202382.50k0.37%
Fideuram Asset Management SGR SpAas of 29 Feb 202466.66k0.30%
More ▼
Data from 30 Jun 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.